GRI BIO, INC. (GRI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 4.07M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 596.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -9.68M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.07M | (m) | $596.00K | $-9.68M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $5.54M | (m) | $604.00K | $-10.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $6.82M | (m) | $793.00K | $-11.98M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $6.09M | (m) | $763.00K | $-11.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $5.48M | (m) | $335.00K | $-10.03M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $4.47M | (m) | $331.00K | $-9.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $3.77M | (m) | $148.00K | $-8.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $3.98M | (m) | $147.00K | $-8.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $4.05M | (m) | $436.00K | $-8.62M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $4.05M | (m) | $412.00K | $-12.29M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $3.23M | (m) | $388.00K | $-11.39M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $3.17M | (m) | $451.00K | $-15.72M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $2.05M | (m) | $125.00K | $-13.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-225.00K | (m) | $3.00K | $-6.64M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.17M | (m) | $99.00K | $-6.93M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $3.53M | (m) | $146.00K | $-8.64M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $3.76M | (m) | $416.00K | $-8.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $4.69M | $0.00 | $639.00K | $-9.29M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $5.19M | $0.00 | $626.00K | $-9.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $3.71M | $100.00K | $154.00K | $-4.79M | (m) | 3707.00% | 154.00% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.